"Partnering With BrainStorm and I AM ALS in the Search for Biomarkers…"

Welcome to Connecting ALS. This week we learn more about The ALS Association’s partnership with I AM ALS to provide a $500,000 grant to BrainStorm to study biomarkers during BrainStorm’s ongoing phase 3 clinical trial of NurOwn.

This week, Mike and Jeremy talk to Dr. Ralph Kern, president and chief medical officer at BrainStorm Cell Therapeutics, and Dr. Kuldip Dave, vice president of research at The ALS Association. Drs. Kern and Dave discuss The ALS Association’s partnership with I AM ALS to provide a $500,000 grant to BrainStorm to study biomarkers during BrainStorm’s ongoing phase 3 clinical trial of NurOwn.

To learn more about the partnership to fund biomarker research read http://www.alsa.org/news/media/press-releases/The-ALS-Association-I-AM-ALS-Award-BrainStorm-Cell-Therapeutics-for-ALS-Biomarker-Study.html

Find a transcript of this episode soon on Tumblr.

This episode was produced by Garrett Tiedemann and is brought to you by The ALS Association’s national office and the Association’s Minnesota/North Dakota/South Dakota Chapter
Brought to you by The ALS Association. © 2020 The ALS Association